A federal appeals court on Tuesday revived a case against AstraZeneca, Sanofi, AbbVie and Novartis over alleged pricing violations under the 340B drug discount program. The companies face renewed claims that they charged unlawfully inflated prices under the federal program, which requires pharmaceutical manufacturers to provide discounted drugs to qualifying healthcare providers.
The 340B program mandates that drug companies sell medications at reduced prices to hospitals and clinics serving low-income and uninsured patients. The program has become increasingly contentious as pharmaceutical companies have implemented restrictions on drug discounts, while healthcare providers argue these limits undermine the program's intent to expand access to affordable medications.
The case was previously dismissed in 2024, but the appeals court decision allows the pricing claims to proceed against the four pharmaceutical giants. The companies now face allegations that their pricing practices violated the statutory requirements of the 340B program, though specific details about the alleged violations were not provided in the available reporting.
The revival of this case could have significant implications for how pharmaceutical companies structure their 340B pricing and discount policies. If successful, the lawsuit could result in financial penalties and force changes to current industry practices around the federal drug discount program, potentially affecting medication access for vulnerable patient populations.